Allovir, Inc. Terminates Material Definitive Agreement
Ticker: KLRS · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Allovir, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $7,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Allovir terminated a key deal on July 1st. Big implications ahead.
AI Summary
Allovir, Inc. announced on July 1, 2024, the termination of a material definitive agreement. The company, formerly known as ViraCyte, Inc., is based in Waltham, MA, and operates in the biological products sector.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction, financial obligations, and future business prospects.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can signal underlying issues or a shift in business strategy, potentially impacting future revenue and operations.
Key Players & Entities
- Allovir, Inc. (company) — Registrant
- ViraCyte, Inc. (company) — Former company name
- July 1, 2024 (date) — Date of earliest event reported
- 001-39409 (other) — Commission File Number
- 83-1971007 (other) — I.R.S. Employer Identification No.
FAQ
What was the specific material definitive agreement that Allovir, Inc. terminated?
The filing states the termination of a material definitive agreement but does not specify which agreement was terminated.
When did the termination of the material definitive agreement become effective?
The earliest event reported is July 1, 2024, indicating the termination likely occurred on or around this date.
What are the potential consequences of this termination for Allovir, Inc.?
The filing does not detail the specific consequences, but termination of material agreements can impact financial standing, partnerships, and strategic operations.
Is there any financial impact disclosed related to this termination?
This specific 8-K filing does not disclose any financial impact resulting from the termination of the agreement.
Does the filing provide any information about the reason for the termination?
No, the filing only reports the termination of a material definitive agreement without providing the reasons behind it.
Filing Stats: 710 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-07-02 16:15:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALVR Nasdaq Glo
- $7,000,000 — ation Payment"), funds in the amount of $7,000,000. The Early Termination Payment shall be
Filing Documents
- d775614d8k.htm (8-K) — 28KB
- d775614dex101.htm (EX-10.1) — 14KB
- 0001193125-24-174335.txt ( ) — 200KB
- alvr-20240701.xsd (EX-101.SCH) — 3KB
- alvr-20240701_def.xml (EX-101.DEF) — 13KB
- alvr-20240701_lab.xml (EX-101.LAB) — 22KB
- alvr-20240701_pre.xml (EX-101.PRE) — 14KB
- d775614d8k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Termination Agreement, dated July 1, 2024, by and between AlloVir, Inc. and BP Bay Colony LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AlloVir, Inc. Date: July 2, 2024 By: /s/ Edward Miller Name: Edward Miller Title: General Counsel